{
    "clinical_study": {
        "@rank": "14941", 
        "biospec_descr": {
            "textblock": "peripheral blood"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell\n      lung cancer"
        }, 
        "brief_title": "VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non Small Cell Lung Cancer", 
            "Brain Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis", 
                "Brain Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. non small cell lung cancer (non squamous carcinoma)\n\n        2. ECOG 0-1\n\n        3. from 18-75 years old"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  non squamous cell non small cell lung cancer\n\n          -  with measurable disease\n\n          -  ECOG 0-1\n\n        Exclusion Criteria:\n\n        - patients received surgery in recent 4 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "advanced non small cell lung cancer patients with brain metastatic disease"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01891708", 
            "org_study_id": "XHZL02"
        }, 
        "intervention": {
            "description": "the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.", 
            "intervention_name": "bevacizumab, standard chemotherapy and radiation", 
            "intervention_type": "Other", 
            "other_name": [
                "Drug:bevacizumab,also Avastine", 
                "Drug:standard chemotherapy recommended by clinical guidlines", 
                "Radiation"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 2, 2013", 
        "location": {
            "contact": {
                "email": "liulixiehe@163.com", 
                "last_name": "Li Liu, MD", 
                "phone": "027-85872015"
            }, 
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430071"
                }, 
                "name": "Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "liulixiehe@163.com", 
            "last_name": "Li Liu, MD", 
            "phone": "027-85872015"
        }, 
        "overall_official": {
            "affiliation": "Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology", 
            "last_name": "Li Liu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01891708"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Huazhong University of Science and Technology", 
            "investigator_full_name": "Li Liu", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "OS", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "Huazhong University of Science and Technology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Li Liu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Months", 
        "verification_date": "July 2013"
    }
}